These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 23918667

  • 1. Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development.
    Karlsson FH, Bouchene S, Hilgendorf C, Dolgos H, Peters SA.
    Drug Metab Dispos; 2013 Dec; 41(12):2033-46. PubMed ID: 23918667
    [Abstract] [Full Text] [Related]

  • 2. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus.
    Heikkinen AT, Baneyx G, Caruso A, Parrott N.
    Eur J Pharm Sci; 2012 Sep 29; 47(2):375-86. PubMed ID: 22759901
    [Abstract] [Full Text] [Related]

  • 3. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F, Poulin P, Nekka F.
    J Pharm Sci; 2010 Jan 29; 99(1):486-514. PubMed ID: 19479982
    [Abstract] [Full Text] [Related]

  • 4. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data.
    Nishimuta H, Sato K, Yabuki M, Komuro S.
    Drug Metab Pharmacokinet; 2011 Jan 29; 26(6):592-601. PubMed ID: 21878741
    [Abstract] [Full Text] [Related]

  • 5. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.
    Gertz M, Harrison A, Houston JB, Galetin A.
    Drug Metab Dispos; 2010 Jul 29; 38(7):1147-58. PubMed ID: 20368326
    [Abstract] [Full Text] [Related]

  • 6. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction.
    Gertz M, Houston JB, Galetin A.
    Drug Metab Dispos; 2011 Sep 29; 39(9):1633-42. PubMed ID: 21632965
    [Abstract] [Full Text] [Related]

  • 7. Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal-systemic concentration difference method.
    Kadono K, Koakutsu A, Naritomi Y, Terashita S, Tabata K, Teramura T.
    Xenobiotica; 2014 Jun 29; 44(6):511-21. PubMed ID: 24329478
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Explication of Definitional Description and Empirical Use of Fraction of Orally Administered Drugs Absorbed From the Intestine (Fa) and Intestinal Availability (Fg): Effect of P-glycoprotein and CYP3A on Fa and Fg.
    Tanaka Y, Kitamura Y, Maeda K, Sugiyama Y.
    J Pharm Sci; 2016 Feb 29; 105(2):431-442. PubMed ID: 26869410
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
    Dufek MB, Bridges AS, Thakker DR.
    Drug Metab Dispos; 2013 Sep 29; 41(9):1695-702. PubMed ID: 23821186
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
    Cai H, Stoner C, Reddy A, Freiwald S, Smith D, Winters R, Stankovic C, Surendran N.
    Int J Pharm; 2006 Feb 03; 308(1-2):133-9. PubMed ID: 16352407
    [Abstract] [Full Text] [Related]

  • 14. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans.
    Takahashi M, Washio T, Suzuki N, Igeta K, Yamashita S.
    J Pharm Sci; 2009 Nov 03; 98(11):4343-53. PubMed ID: 19230019
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam.
    Kuze J, Mutoh T, Takenaka T, Oda N, Hanioka N, Narimatsu S.
    Xenobiotica; 2013 Jul 03; 43(7):598-606. PubMed ID: 23282066
    [Abstract] [Full Text] [Related]

  • 16. In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications.
    Cho HJ, Kim JE, Kim DD, Yoon IS.
    Drug Dev Ind Pharm; 2014 Aug 03; 40(8):989-98. PubMed ID: 23981203
    [Abstract] [Full Text] [Related]

  • 17. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS, Bolger MB, Walker DK, Kaddoumi A.
    Mol Pharm; 2012 Mar 05; 9(3):492-504. PubMed ID: 22264132
    [Abstract] [Full Text] [Related]

  • 18. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys.
    Nishimuta H, Sato K, Mizuki Y, Yabuki M, Komuro S.
    Drug Metab Dispos; 2010 Nov 05; 38(11):1967-75. PubMed ID: 20702772
    [Abstract] [Full Text] [Related]

  • 19. Baicalin pharmacokinetic profile of absorption process using novel in-vitro model: cytochrome P450 3A4-induced Caco-2 cell monolayers combined with rat intestinal rinse fluids.
    Morisaki T, Hou XL, Takahashi K, Takahashi K.
    J Pharm Pharmacol; 2013 Oct 05; 65(10):1526-35. PubMed ID: 24028620
    [Abstract] [Full Text] [Related]

  • 20. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS, Hatch HL, Kosea F, Nguyen HT, Choo EF, McClure KF, Taylor TJ, Henne KR, Kuperman AV, Dombroski MA, Letavic MA.
    Biopharm Drug Dispos; 2006 Nov 05; 27(8):371-86. PubMed ID: 16944451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.